3SBio (FRA:83B) ROCE % : 9.17% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is 3SBio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 3SBio's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.17%.

3SBio ROCE % Historical Data

The historical data trend for 3SBio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio ROCE % Chart

3SBio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

10.52

7.14

11.92

12.40

10.65

3SBio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															10.38	12.77	12.40	12.58	9.17

3SBio ROCE % Calculation

3SBio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	281.354	/	( ( (2980.114 - 249.674)	+	(3034.11 - 478.729) )	/ 2 )
	=	281.354	/	( (2730.44	+	2555.381)	/ 2 )
	=	281.354	/	2642.9105
	=	10.65 %

3SBio's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	233.176	/	( ( (2986.264 - 458.786)	+	(3034.11 - 478.729) )	/ 2 )
	=	233.176	/	( ( 2527.478	+	2555.381 )	/ 2 )
	=	233.176	/	2541.4295
	=	9.17 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3SBio (FRA:83B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

3SBio ROCE % Related Terms

Thank you for viewing the detailed overview of 3SBio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (FRA:83B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (FRA:83B) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

01530:Hong Kong 83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (FRA:83B) Headlines

No Headlines